MicroRNAs in β-Cell Biology, Insulin Resistance, Diabetes and Its Complications by Fernandez-Valverde, Selene L. et al.
MicroRNAs in b-Cell Biology, Insulin Resistance,
Diabetes and Its Complications
Selene L. Fernandez-Valverde, Ryan J. Taft, and John S. Mattick
M
icroRNAs (miRNAs) are small 19–23 nucleo-
tide RNA molecules that act as regulators of
protein expression in eukaryotic cells by in-
ducing the translational arrest and degrada-
tion of messenger RNAs (1). They are potent drivers of
differentiation and development (1), and their dysregula-
tion has been linked to many diseases. Here, we present an
overview of the known and proposed roles and effects of
miRNAs in type 1 and type 2 diabetes (T1D and T2D), fo-
cusing on b-cell biology, insulin resistance, and diabetes
complications. Speciﬁcally, we discuss miRNAs in b-cell
biology, altered expression of miRNAs in adipose tissue in
response to obesity, and miRNA dysfunction in organs and
tissues that may be affected in later stages of the disease.
Additionally, we propose a set of research directions that
may yield novel diagnostic and therapeutic approaches for
this chronic illness.
T2D is characterized by hyperglycemia resultant from
impaired insulin secretion and/or impaired insulin action
in peripheral tissues (2). T2D constitutes one of the greatest
pandemics of our time, with 220 million people currently
diagnosed (3), and 366 million people expected to be af-
fected by 2030 (4). A number of lines of evidence support
a key role for pancreatic b-cell dysfunction in T2D (in
addition to T1D), in which it is the major pathology. For
example, recent genome-wide association studies have
strongly implicated genes involved in insulin secretion as
etiological factors in the development of T2D (5).
A role for miRNAs in T2D was ﬁrst established in 2004
by Poy et al. (6) who showed that miR-375 is directly in-
volved in the regulation of insulin secretion. This study
was one of the ﬁrst to demonstrate that a miRNA could
be tightly linked to a disease phenotype. In recent years,
dozens of additional miRNAs have been identiﬁed as
components of pathways triggered by, or contributing to,
the pathology of both T1D and T2D (Table 1). Because of
the multifactorial and polysystemic nature of this disease
and the increased interest in miRNAs, it seems likely that
many more miRNAs, and perhaps other small regulatory
RNA species, will be identiﬁed as factors in diabetes. This
will undoubtedly lead to a greater understanding of the
genetic basis of the disease and provide novel diagnostic,
prognostic, and treatment alternatives.
miRNAS IN b-CELL BIOLOGY
Pancreatic b-cells play a fundamental role in glucose ho-
meostasis, releasing insulin in response to glucose levels in
the bloodstream. Insulin then triggers glucose uptake in its
target tissues, such as the liver, kidney, skeletal muscle,
and cardiac muscle. Absence or malfunction of b-cells
leads to diabetes due to lack of insulin producing cells
(T1D), or to the inability to increase insulin levels to suf-
ﬁciently stimulate glucose uptake in the face of insulin
resistance (T2D).
In T1D, the lack of insulin is primarily caused by the
absence or destruction of pancreatic b-cells, which is
driven by developmental errors or immune malfunction,
respectively. A large suite of miRNAs has been implicated
in pancreas (and therefore b-cell) development including
miR-15a/b, miR-16, miR-195 (7), miR-503, miR-541, miR-214
(8), miR-9 (9), miR-124a (10), miR-7 (9,11), miR-376 (9) and
miR-375 (9,12), among others. There remains a need for
detailed studies of the role of these miRNAs in diabetes,
but it is clear that mutations or misexpression of these
species could lead to b-cell pathologies (see below).
Likewise, miRNAs have been implicated in the autoim-
mune destruction of b-cells, also leading to T1D. Recently,
Hezova et al. (13) measured changes in miRNA expression
in regulatory T cells (T-reg cells) of T1D-affected individu-
als. These cells are of special interest as they are critical
regulators of autoimmune disease. They found that miR-510
was signiﬁcantly upregulated, and miR-191 and miR-342
were signiﬁcantly downregulated in adult peripheral T-reg
cells of diabetic patients compared with healthy individuals
(13). miR-342 is also known to show altered expression
proﬁles in hematological disease (14,15). These observa-
tions suggest a role for these miRNAs in the autoimmune
destruction of b-cells.
The role of miRNAs in the function of b-cells in T2D
patients has been extensively studied but is not yet fully
understood, as exempliﬁed by miR-375. In adult b-cell
islets miR-375 levels are decreased when high levels of
glucose are available (6). Low levels of miR-375 induce
insulin secretion by de-repression of its targets Mtpn (6,16)
and PDK1 (17,18), while overexpression of miR-375 at-
tenuates proliferation and insulin gene transcription while
reducing glucose-induced insulin secretion (16,18,19). In-
deed, ectopic expression of miR-375 in diabetic pancreatic
b-cells results in increased susceptibility to fatty acid in-
duced apoptosis (16). Consistent with these studies, high
levels of miR-375 are present in pancreatic islets of obese
diabetic mouse models (ob/ob) (20) and T2D affected
individuals (21). Additionally, when miR-375 is deleted in
ob/ob mice, they develop a marked decrease in b-cell mass,
which results in a severe insulin-deﬁcient diabetes not
found in ob/ob mice (20). Overall, it is becoming clear that
miR-375 targets a suite of genes that negatively regulate
cellular growth and proliferation (20), and that aberrant
loss of this miRNA leads to dramatic reduction of b-cell
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PERSPECTIVES IN DIABETESTABLE 1
miRNAs involved in diabetes
miRNA Tissue Relevance to diabetes References
miR-375 Pancreas Expressed in pancreatic development. Regulates
insulin secretion in b-cells and increases their
death by lipoapoptosis, as it regulates this cell
viability and proliferation. Upregulated in
b-cells of T2D patients. Its deletion causes
severe insulin-deﬁcient diabetes in ob/ob mice.
(6,8,9,12,16,18–21,69)
miR-29(a/b/c) Adipose Induced by high glucose and high insulin.
Overexpression leads to insulin resistance.
(31,32,70)
miR-143 Adipose Participates in adipocyte differentiation and is
induced in adipogenesis and downregulated in
obesity.
(41,42)
miR-9 Pancreas, cardiac muscle Expressed in pancreatic development. Impairs
insulin secretion in b-cells and is upregulated
in cardiomyocytes of STZ-induced diabetic
mice.
(9,22)
miR-124a Pancreas Upregulated by glucose. Regulates the insulin
exocytosis pathway, causing exaggerated
insulin release when no glucose is available
but reduced glucose-induced insulin secretion.
(10,23,24)
miR-195 Pancreas, liver Expressed in pancreatic development and
upregulated in liver of diabetic rats.
(7,32)
miR-192 Kidney Induced by transforming growth factor-b and
highly expressed in glomeruli of STZ-induced
diabetic mice. Targets SIP1.
(59)
miR-222 Adipose Upregulated in response to high glucose in
adipose tissue of diabetic rats.
(32)
miR-126 Pancreas, skeletal muscle Expressed in pancreatic development.
Upregulated in skeletal muscle of GK rats and
in livers of ob/ob mice compared with STZ
mice.
(8,56,71)
miR-133a Cardiac and skeletal muscle Overexpressed in rabbit diabetic heart, where it
induces prolongation of QT interval.
Downregulated in cardiac hypertrophy in
mouse and human hearts and in hearts of STZ-
induced diabetic mice. Also reduced in human
skeletal muscle in T2D. High fasting glucose
associates with lower expression of this
miRNA.
(45,46,48,53,54,72)
miR-296 Pancreas Expressed in b-cell islets and upregulated by
glucose.
(18)
miR-96 Pancreas Negatively regulates insulin exocytosis through
upregulation of granuphilin.
(23)
miR-34a Pancreas, liver Increases in b-cells in response to palmitate,
making them more susceptible to death by
apoptosis and inhibiting nutrient-induced
insulin secretion. Upregulated in the livers of
STZ-induced diabetic mice. Found in the
bloodstream and can differentiate between
nondiabetic and early T2D patients.
(23,56,73,74)
miR-146b Pancreas Contributes to increased apoptosis of b-cells.
Expression induced by cytokines and sodium
palmitate.
(72,74)
miR-657 Liver Regulates insulin-like growth factor 2 receptor,
and variants in its regulation site (changes in
regulation) give predisposition to diabetes.
(75)
miR-30d Adipose Upregulated in presence of high glucose,
upregulates insulin gene transcription.
(24)
miR-320 Cardiac vascular endothelium Upregulated in GK rats with impaired
angiogenesis.
(76)
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thus diabetes.
At least three additional miRNAs play a critical role in
insulin exocytosis in b-cells. For example, miR-9 positively
regulates glucose-induced insulin secretion in b-cells by di-
rectly repressing Onecut-2, the granuphilin (synaptotagmin-
like 4) repressor, a protein that signiﬁcantly enhances
basal, but strongly inhibits K
+-induced insulin secretion
(22). Likewise, miR-96 also negatively regulates insulin exo-
cytosis by targeting synaptotagmin-like 4 (23), and reduces
levels of Noc2, which impairs b-cell ability to respond to
secretagogues (23). The third well-described b-cell miRNA,
miR-124a, intriguingly, appears to link b-cell and neural
biology through the exocytosis pathway. miR-124a is
TABLE 1
Continued
miRNA Tissue Relevance to diabetes References
miR-103 Pancreas, liver Overexpression accelerates adipogenesis.
Reduced in response to TNF-a. Downregulated
in obesity. Upregulated in liver of ob/ob mice
(vs. STZ-induced diabetic mice) and diabetic
rats.
(32,41,56)
miR-107 Pancreas, adipose Overexpression accelerates adipogenesis.
Reduced in response to TNF-a. Upregulated in
b-cells in presence of high glucose.
(24,41)
miR-1 Cardiac and skeletal muscle Regulates cardiac arritmogenic potential.
Upregulated by high glucose in
cardiomyocytes, where it accelerates
apoptosis. High levels found in ventricle of
diabetic patients. Impaired insulin response in
skeletal muscle of T2D patients. Signiﬁcantly
downregulated in the heart of STZ-induced
diabetic mice.
(45,51,53,55,77)
miR-223 Heart Upregulated in the insulin-resistant heart, where
it increases glucose uptake through increase of
Glut4.
(78)
miR-125(a/b) Liver, vascular tissue Upregulated in liver of hyperglycemic rats.
Increase of this miRNA results in
a proinﬂammatory diabetic phenotype in
vascular smooth muscle cells.
(31,79)
miR-27(a/b) Adipose Impairs human adipocyte differentiation and
targets peroxisome proliferator–activated
receptor g. Upregulated in adipose tissue of
diabetic rats and by glucose in 3T3 adipocytes.
(32,34)
miR-216a, miR-217 Kidney Highly expressed in kidney and upregulated by
transforming growth factor-b. Activates Akt
signaling through targeting of PTEN.
(60,80)
miR-122 Liver Suppression in liver results in reduced fatty acid
accumulation. Downregulated in liver of STZ-
induced diabetic mice.
(56,57)
miR-320 Adipose, vascular endothelium Highly upregulated in insulin-resistant
adipocytes. Targets p85, leading to increased
insulin resistance in adipocytes. Upregulated
in myocardial microvascular cells in GK rats,
where it impairs angiogenesis.
(33,76)
miR-21 Pancreas, liver Upregulated by nuclear factor-kB and fatty acids
in liver, leading to downregulation of its target
PTEN. Induced by interleukin-1b and TNF-a in
pancreatic islets. Expression increased in rats
on high-fat diet and in liver of T2D patients.
Overexpression reduces maximal glucose-
induced insulin release in b-cells.
(58,74)
miR-206 Cardiac and skeletal muscle Upregulated in skeletal muscle of diabetic and
prediabetic patients. Upregulated by high
glucose in cardiomyocytes. Accelerates
cardiomyocyte apoptosis.
(48,55)
miR-93 Vascular endothelium Downregulated by high glucose through
downregulation of its host gene MCM7.
(81)
miR-30a* Adipose Downregulated in T2D individuals, independent
of obesity.
(68)
miR-181d Liver Most effective miRNA at reducing intracellular
lipid content of hepatocytes.
(82)
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was ﬁrst described as a brain-speciﬁc miRNA implicated in
neurogenesis (25). High levels of miR-124a in b-cells lead
to exaggerated insulin release at low-glucose concentra-
tions but reduced glucose-induced secretion (24). This is
likely to the result of targeting of Foxa2, which in turn
downregulates Sur-1, Kir6.2, and Pdx1, the latter of which
directly regulates the expression of the insulin gene (10).
miR-124a also decreases levels of Rab27a and Noc2 and
upregulates Snap25, Rab3a, and Synapsin1a, facilitating
tight regulation of the insulin exocytosis pathway (23).
Interestingly, two other miRNAs, miR-7 (26) and miR-
375 (12), are expressed both in brain and in b-cell islets.
Both b-cells and neurons share similar secretion mecha-
nisms and are responsive to signals in the bloodstream
including glucose and insulin. Taking into account the fact
that insulin stimulates glucose metabolism in the brain,
mainly in the cerebral cortex (27), it is likely that miRNA
expression in the brain is affected by diabetes, which
could therefore have profound neurologic consequences.
miRNAS IN OBESITY AND ADIPOSE TISSUE
Obesity, hyperlipidemia (elevated levels of blood lipids),
and insulin resistance (reduced glucose uptake in re-
sponse to the insulin signal) are strongly associated with
the onset of T2D (28). Obesity itself is characterized by
adipocyte dysfunction with abnormalities in adipokine
secretion and in energy metabolism. Adipogenic abnor-
malities lead to an adipocyte phenotype distinct from the
“ideal” which stores excess energy benignly in the tri-
glyceride droplet. Among other downstream effects, this
leads to an accumulation of fat in ectopic sites, such as
liver, muscle, pancreas, and kidneys (29). It also leads to
the secretion of chemoattractants that promote macro-
phage inﬁltration of adipose tissue, leading to inﬂamma-
tion and excessive release of free fatty acids into the
bloodstream (29,30).
miRNAs in adipose tissue are strongly dysregulated in
response to obesity-induced molecular changes and en-
vironmental signals. For instance, the expression of the
miR-29 family is induced by hyperglycemia and hyper-
insulinemia in adipose tissue (31), and miR-29a is highly
upregulated in 3T3-L1 adipocytes in response to high glu-
cose (32). Likewise, miR-320 increases insulin sensitivity
of insulin resistant adipocytes (33) and miR-27b impairs
human adipocyte differentiation (34). These miRNAs tar-
get conserved core cell-regulatory pathways that are af-
fected both locally and systematically by obesity and by
diabetes generally. Indeed, miR-320 targets p85, which
plays a critical role in cell growth by increasing Akt
phosphorylation and thus the level of Glut4 (33). Similarly,
miR-29 targets p85a in HeLa cells, and is thus likely
to affect Akt signaling in adipocytes (35). Additionally,
miR-27b targets peroxisome proliferator–activated receptor
g (34), the nuclear receptor targeted by thiazolidinediones,
an insulin-sensitizing agent used for treating T2D (36). Just
as miRNAs are diagnostic of broad changes in cancer
(37,38), they also reﬂect the degree of disturbance in di-
abetes.
As mentioned above, obesity triggers macrophage in-
ﬁltration and cytokine release in adipose tissue. This is
closely followed by changes in miRNA expression, which
in turn affect lipid levels and adipogenesis. Indeed, many
cytokines, such as tumor necrosis factor (TNF)-a, interfere
with insulin signaling and inhibit adipogenesis (39,40) and
several miRNAs that are induced during adipogenesis are
downregulated in obesity (41). For example, inhibition of
miR-143 has been shown to regulate adipocyte differenti-
ation and results in reduced adipogenesis (42). Similarly,
miR-103 and miR-107 have been shown to accelerate adi-
pogenesis (43), and are predicted to target pathways that
regulate cellular acetyl-CoA and lipid levels (44). Levels of
miR-143, miR-103 and miR-107 are reduced after one-day
treatment with TNF-a in adipocytes (43), suggesting that
macrophage inﬁltration and cytokine release are a con-
tributing factor to reduced adipogenesis in obesity. The
connection between miRNA expression and cytokine ex-
posure may eventually be leveraged into treatment options
for morbidly obese diabetic patients.
miRNAS IN DIABETES COMPLICATIONS
Tissues adversely affected by diabetes may include cardiac
and skeletal muscle, liver, kidney, and endothelium. Hy-
perglycemia and hyperlipedemia damage these tissues
causing conditions such as fatty liver, stroke, kidney fail-
ure, neuropathy, and blindness. Not surprisingly, the ex-
pression of miRNAs is altered in these tissues in diabetic
individuals.
A precondition for the onset of T2D is insulin resistance
of skeletal muscle. Abnormally circulating fatty acids
accumulate in skeletal muscle and disrupt important
signaling pathways (29). Normally, insulin activates the
transcription of sterol regulatory element–binding protein
1, which represses transcription of miR-1 and miR-133 by
inhibiting muscle speciﬁc factor myocyte enhancer factor
(MEF) 2C (45,46). The repression of miR-133a and miR-1
in response to insulin levels is impaired in T2D patients
(45), which contributes to impaired muscle function (47).
Indeed, a recent study has shown that the expression of
miR-133a is strongly downregulated in this tissue in T2D-
affected individuals (48).
The miRNAs miR-1 and miR-133 also play a primordial
role in normal cardiac function and cardiogenesis (49,50).
In the normal heart, cardiomyocytes exposed to high levels
of glucose develop hypertrophy and, similar to skeletal
muscle, have low levels of miR-133a (51). Indeed, glucose-
induced cardiomyocyte hypertrophy is associated with
increased levels of MEF2A and MEF2C (52). In diabetes,
however, the relationship between MEF2A/C is impaired.
miR-133 is in fact overexpressed in the rabbit diabetic
heart, where it induces prolongation of the QT interval,
a known phenotype of T2D (53). However, and surpris-
ingly, both miR-1 and miR-133a are downregulated in the
hearts of mice with insulin-deﬁciency induced by strepto-
zotocin (STZ), and in cardiac-hypertrophy and heart failure
(54). This strongly suggests that the relationship between
miR-133 and miR-1 and cardiomyocte responses to insulin
and glucose is complex. Indeed, a recent study has shown
that these miRNAs are upregulated in cardiomyocytes
after high-glucose exposure (55), which accelerates car-
diomyocyte apoptosis (55), a key factor in the development
of diabetic cardiomyopathy. These observations suggest
that miR-1 and miR-133 are excellent candidates for further
functional studies. Unraveling their seemingly contradictory
behavior will undoubtedly shed light on the complicated
biology underpinning muscle cell responses to physiolog-
ical stimuli.
In the late stages of diabetes, liver and kidney function
may be impaired, and this is reﬂected in several abnor-
mal miRNA expression proﬁles. For example, inhibition of
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downregulated in the livers of STZ-induced diabetic mice
(56), results in low plasma cholesterol levels, increased
hepatic fatty acid oxidation, and decreased hepatic fatty
acid and cholesterol synthesis rate (57). miR-21 also plays
an important role in hepatocytes, where it is induced by
nuclear factor-kB, leading to the downregulation of phos-
phatase and tensin homolog (PTEN), a protein that inhibits
Akt activation (58). High-fat diets result in the upregulation
of miR-21 in rats (58), and liver biopsies of obese human
patients also show an increase in the expression of miR-21
and a decreased level of PTEN expression in comparison
with normal controls (58). In the diabetic kidney, tran-
forming growth factor-b and miR-192 induce expression of
miR-216a and miR-217 (59,60), which leads to activation
of Akt through targeting of PTEN (60).
A tissue that has recently come to attention in diabetes
is vascular endothelium, which changes in response to
diabetic inﬂammatory signals. There is a strong negative
correlation between miR-126 levels and the onset of di-
abetic vascular complications (61). However, this miRNA
is signiﬁcantly increased in patients suffering of coronary
artery disease (62). Interestingly, delivery of this miRNA
by apoptotic bodies protects against diet-induced athero-
sclerosis (62). This indicates that miR-126 can be used as
both a biomarker for early detection of vascular compli-
cations of diabetes, and as a possible RNA-based thera-
peutic for diabetes-induced atherosclerosis.
FUTURE CHALLENGES AND POSSIBILITIES
There are many areas of research that remain unexplored
in relation to miRNAs and diabetes. One is the interplay
between the brain and insulin target tissues. It is known
that the brain is fueled by glucose and, despite previous
reports that this tissue is insulin insensitive, recent articles
have shown insulin-induced glucose uptake in speciﬁc
brain regions (27). Indeed, the similarities between b-cell
and neuronal exocytosis systems are remarkable (see
above). Due to the fact that the brain is responsible for
behavioral control, it is likely that it reacts directly to the
availability or depletion of glucose in the bloodstream by
regulating caloric uptake. miRNAs have already been
shown to carry out important regulatory functions in the
brain, and therefore a study focusing on the miRNA
changes in brain in response to hyperglycemia and hy-
perlipidemia is essential for a complete systemic under-
standing of diabetes.
It is now clear that the miRNA proﬁle of insulin re-
sistance tissues changes years before the onset and/or di-
agnosis of T2D. Indeed, a study by Zampetaki et al. (61) has
shown that a plasma signature of ﬁve miRNAs (miR-15a,
miR-29b, miR-126, miR-223, and miR-28–3p) can accurately
differentiate patients with a high likelihood of developing
diabetes from healthy controls. In a review, Regazzi (63)
proposed that these miRNAs might not only be indicators
of early disease onset but are also responsible for its
progression and thus a good target for early intervention.
One possibility is that these miRNAs actually act distant
from their sites of biogenesis, and are transmitted from
one tissue to another (64). The recent observation of
miR-150 transmission through the bloodstream and uptake
by target endothelial cells (65) makes this possibility
likely. If diabetes-related miRNAs are trafﬁcked in trans,
it may be possible to interfere in the progression of the
disease with minimally invasive RNA therapeutics.
Because of the high genetic predisposition of some in-
dividuals to develop T2D, identiﬁcation of genetic variants
that alter the levels of key miRNAs may become a clini-
cally powerful tool, undoubtedly aided by the increasing
affordability of personal genomic sequencing. We predict
that the availability of this technology will provide clini-
cians with an invaluable tool to identify at-risk individuals,
to prompt their patients to take preventive action, and,
eventually, to prescribe tailored therapeutics (66). It will
also provide a baseline for beginning to rigorously identify
environmental factors that promote epigenetic variations,
particularly for genetically susceptible individuals.
It is important to emphasize the need for integrating cur-
rent and future miRNA studies into existing resources like
the Beta Cell Biology Consortium (http://www.betacell.org/).
Many recent genome-wide studies have provided a snapshot
of the miRNA content of different tissues involved in this
disease, including the developing pancreas (67) and sub-
cutaneous adipocytes of T2D patients (68). However, it is
difﬁcult to integrate this information if it is not summarized
in a central repository. As highlighted by Gallagher et al.
(48), even though the community hoped to gain insight into
miRNA mechanisms of action by studying them in isolated
model systems, it is now clear that this information must be
centralized and integrated with clinical data in order to ob-
tain the insights necessary to conquer this illness.
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